Skip to main content

Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)



The durability of immune responses to COVID-19 vaccines among older people living with HIV (PWH) is clinically important.


We aimed to assess vaccine-induced humoral immunity and durability in older PWH (≥ 55 years, n = 26) over 6 months (post-initial BNT162b2 series). A secondary and exploratory objective was to assess T-cell response and BNT162b2 booster reactogenicity, respectively. Our Visit 1 (3 weeks post-initial BNT162b2 dose) SARS-CoV-2 humoral immunity results are previously reported; these subjects were recruited for Visit 2 [2 weeks (+ 1 week window) post-second vaccination] and Visit 3 [6 months (± 2 week window) post-initial vaccination] in a single-center longitudinal observational study. Twelve participants had paired Visit 2/3 SARS-CoV-2 Anti-Spike IgG data. At Visit 3, SARS-CoV-2 Anti-Spike IgG testing occurred, and 5 subjects underwent T-cell immune response evaluation. Thereafter, subjects were offered BNT162b2 booster (concurrent day outside our study) per US FDA/CDC guidance; reactogenicity was assessed. The primary study outcome was presence of detectable Visit 3 SARS-CoV-2 Anti-Spike-1-RBD IgG levels. Secondary and exploratory outcomes were T-cell immune response and BNT162b2 booster reactogenicity, respectively. Wilcoxon signed-rank tests analyzed median SARS-CoV-2 Anti-Spike IgG 6-month trends.


At Visit 3, 26 subjects underwent primary analysis with demographics noted: Median age 61 years; male n = 16 (62%), female n = 10 (38%); Black n = 13 (50%), White n = 13 (50%). Most subjects (n = 20, 77%) had suppressed HIV viremia on antiretroviral therapy, majority (n = 24, 92%) with CD4 > 200 cells/µL. At Visit 3, 26/26 (100%) had detectable Anti-Spike-1-RBD (≥ 0.8 U/mL). Among 12 subjects presenting to Visit 2/3, median SARS-CoV-2 Anti-Spike 1-RBD was 2087 U/mL at Visit 2, falling to 581.5 U/mL at Visit 3 (p = 0.0923), with a median 3.305-fold decrease over 6 months. Among subjects (n = 5) with 6-month T-cell responses measured, all had detectable cytokine-secreting anti-spike CD4 responses; 3 had detectable CD4 + Activation induced marker (AIM) + cells. Two had detectable cytokine-secreting CD8 responses, but all had positive CD8 + AIM + cells.


Among older PWH, SARS-CoV-2 Anti-Spike IgG and virus-specific T-cell responses are present 6 months post-primary BNT162b2 vaccination, and although waning, suggest retention of some degree of long-term protective immunity.

Peer Review reports


Highly effective, novel mRNA vaccines were developed precipitously for prevention of 2019 Coronavirus disease (COVID-19), resulting in significantly decreased morbidity, mortality [1,2,3].

Key determinants of vaccine efficacy emerged following global COVID-19 vaccine rollout [4], including host factors (i.e. age, immunocompromised status), viral factors (i.e. variants of concern (VOC)/sub-variants exhibiting varying immune evasion levels), and vaccine-related factors (i.e. waning immune responses). These factors interact to cause increased susceptibility to SARS-CoV-2 infection/reinfection and have led to additional vaccine doses (boosters). However, key factors that should inform booster vaccine frequency are robustness, breadth, durability of immune responses to vaccination over time, correlated with clinical outcomes.

Incomplete information on COVID-19 vaccination durability in those with underlying immune dysregulation remains—particularly in people living with HIV (PWH). Therefore, we sought to assess level, breadth, durability of immune responses 6 months post-primary COVID-19 vaccination among older PWH.


A cohort of PWH (≥ 55 years) who received BNT162b2 COVID-19 vaccination primary series at Yale New Haven Health System (YNHHS) vaccination sites were followed over 6 months. Individuals with prior laboratory-confirmed or breakthrough COVID-19 were excluded.

Subjects were recruited from a prepopulated schedule prior to visit/on-site for 3 visits: Visit 1 [3 weeks post-first vaccination (published previously [5])]; Visit 2 [2 weeks (+ 1 week window) post-second vaccination]; Visit 3 [6 months (± 2 week window) post-first vaccination].

SARS-CoV-2 semi-quantitative Anti-Spike 1-RBD IgG was performed (Roche Elecsys, under US FDA Emergency Use Authorization [99.5% sensitivity, 99.8% specificity]) on cryopreserved sera (Visit 2), and fresh sera (Visit 3) to determine Visit 2/3 antibody levels. Positive SARS-CoV-2 qualitative anti-nucleocapsid antibody (Roche Elecsys) led to exclusion of subjects with COVID-19 history from analyses.

SARS-CoV-2 vaccine T-cell immunogenicity testing

Cryopreserved PBMCs were thawed, rested, and cultured (6-h) in SARS-CoV-2 peptide pool (1 μg/ml, Miltenyi Biotec), then stained for intracellular cytokine stating (ICS) assay, and co-stimulated with anti-CD28/anti-CD49d for activation induced marker (AIM) assay. Antibodies (Biolegend): anti-CD3 (UCHT1), anti-CD4 (SK3), anti-TNF-α (MAb11), anti-OX40 (Ber-ACT35), anti-CD137 (4B4-1), anti-CD69 (FN50, Biolegend); Antibodies (BD Biosciences): anti-CD8 (SK1), anti-IFN-γ (B27). Flow cytometry data was acquired on LSRFortessa and analyzed by FlowJo v.10.8.0.

Data collection

Electronic medical record review yielded subject demographics, body mass index (BMI), co-morbidities including immunosuppressed status, HIV history (duration, antiretroviral therapy (ART), recent CD4, viral load).

Statistical analysis

Data distribution was non-Gaussian; thus, non-parametric paired analysis (Wilcoxon signed-rank test) using Stata (v16.1) compared Visit 2/3 antibody levels. Statistical significance was determined at p-value < 0.05.

Ethical approval

This study received Yale Human Investigations Committee and Institutional Review Board approval (HIC # 200030266) and written informed consent from subjects was obtained.


Thirty-one met inclusion criteria (5 excluded [COVID-19 history (n = 3), pre-Visit 3 booster recipients (n = 2)]). Twenty-six were included in primary analysis (Demographics, Co-morbidities, SARS-CoV-2 antibody results in Table 1). All took ART, majority (n = 24, 92%) had CD4 > 200 cells/µL, and 20/26 were virologically suppressed; 6 had detectable viremia (< 100 copies/mL). All 26 participants (100%) had detectable Visit 3 Anti-Spike-1-RBD IgG [reference < 0.8 U/mL] (Fig. 1/Table 1). In a subset participating in both Visits 2 and 3 (n = 12) median SARS-CoV-2 Anti-Spike 1-RBD was 2087 U/mL (n = 12) at Visit 2, which fell to 581.5 U/mL (n = 12) at Visit 3 (p = 0.0923), reflecting a 6-month median 3.305-fold decrease (Fig. 1a) though not statistically significant. Median SARS-CoV-2 Anti-Spike 1-RBD for all Visit 3 subjects (n = 26) was 492 U/mL (Fig. 1b). Using a clinical correlate of Anti-Spike-1-RBD antibody ≥ 100 U/mL as a disease protection threshold [6], 22/26 (84.6%) met positivity criterion. Four subjects were sub-threshold: One had chronic kidney disease (CKD); 3 had multiple co-morbidities, including heart transplant on tacrolimus (1), CKD (1), and morbid obesity (1) (Table 1).

Table 1 Participant demographics, co-morbidities, and SARS-CoV-2 antibody results

Eighteen Visit 3 subjects receiving BNT162b2 booster had reactogenicity evaluated 1-week post-booster. All subjects (100%) reported ≥ 1 mild-moderate symptom (Fig. 3): Injection site pain 61% (n = 11); fatigue 17% (n = 3); chills, headaches, or myalgias 11% (n = 2); nausea or malaise 6% (n = 1). Among these subjects, a cohort (n = 5) had T-cell immunologic responses analyzed (Fig. 2). All (n = 5) had detectable cytokine-secreting anti-spike CD4 responses; 3 had detectable CD4 + AIM + cells. Two had detectable cytokine-secreting CD8 responses, but all (n = 5) had positive CD8 + AIM + cells.


Our study results demonstrate there are detectable circulating anti-spike RBD antibodies 6-months post-primary COVID-19 BNT162b2 vaccination series in older PWH. Guidelines for PWH have described older PWH as people who are 50 years of age or older [7]. Using a threshold of Anti-Spike-1-RBD antibody ≥ 100 U/mL as a correlate of COVID-19 protection [6], it is remarkable that 84.6% of subjects met 6-month threshold criterion. Of note, there is limited data regarding the clinical applicability of using this Elecsys Anti-SARS-CoV-2 S RBD assay and the implications of its semi-quantitative antibody levels as it relates to the degree of immunity or protection against COVID-19 in vaccinated individuals [8]. Our cohort had significant variability and rather broad range of Anti-Spike-1-RBD levels, which may reflect participant characteristics, co-morbidities influencing vaccine responses. Four subjects below the clinical correlate of protection had multiple co-morbidities, including CKD in the majority, and 1 heart transplant recipient on tacrolimus. Our cohort, though older, were virologically suppressed, most with CD4 > 200 cells/µL. Thus, underlying HIV may not have negatively influenced vaccine responses, unlike those with lower CD4 counts, as observed in other studies.

We found significant circulating antibody waning over time, as observed in other cohorts. Waning immunity has been associated with clinical endpoints of increased vulnerability to SARS-CoV-2 infection/reinfection, particularly where circulating VOC demonstrate significant immune evasion. Thresholds at which these events occur must be well-defined. Thus, it is important to correlate immune responses (including qualitative/quantitative) with clinical outcomes, among different populations/hosts, to inform immunologic assessment, clinical significance—and importantly—vaccine booster frequency.

Much attention has been given to assessing cell-mediated immune responses post-COVID-19 vaccination. While circulating neutralizing antibodies emerged as primary correlate of protection against infection, memory B- and T-cells—which modulate adaptive immune responses, acting as effector cells—serve as secondary lines of defense against disease progression and severity following SARS-CoV-2 infection and may exhibit greater durability [9]. Though T-cell responses were assessed in a small cohort, the robust persistence of SARS-CoV-2 Spike-specific and functional T-cells 6-months post-primary mRNA vaccination among older PWH is encouraging, warranting exploration. Spike-specific T-cells generated by BNT162b2 exhibit wide breadth and retain activity against emerging VOC [10], although their immunoprotective role is not well-defined.

Regarding reactogenicity, booster vaccine was well-tolerated. Most experienced local injection site pain with limited systemic reactogenicity, on par with other booster dose studies [11].

Our study has important limitations. Our single academic center cohort comprised PWH ≥ 55 years with well-controlled HIV, robust CD4 counts, which may not represent HIV-infected cohorts with dissimilarities and a younger cohort of people living with HIV [12]. However, it does provide important insight about older PWH, a demographic increasing annually as majority of US PWH are ≥ 50 years [7]. We evaluated response to a specific mRNA vaccine, so findings may not extrapolate to other (mRNA) vaccines/platforms. Although we lacked an HIV-uninfected control group, immune responses published among other cohorts provide context for interpreting our data. Notwithstanding, the absence of standardized antibody assays remains challenging for direct study result comparison. Thus, a more standardized method of assessing SARS-CoV-2 humoral immunity and correlates of immune protection is needed; ongoing research is being conducted to establish international standards to interpret humoral immunity results using different testing platforms and units of measurement [8]. We excluded participants with prior or breakthrough COVID-19, so as not to bias immunologic assessments, which may inadvertently select for more optimal vaccine responses.


Our prior data highlighted the importance of 2-dose COVID-19 primary vaccination series in older PWH [5]. This study demonstrates that though there is waning immunity by 3.305-fold over 6-months post-primary COVID-19 vaccination, there is a degree of retention of humoral immunity among most older PLWH. A sub-study revealed presence of Spike-specific T-cell responses. Our findings suggest that older PWH retain immunologic benefit from vaccination 6-months post-vaccination, though booster doses are needed to maintain optimal antibody levels over time.

Fig. 1
figure 1

a Quantitative assessment of SARS-CoV-2 Spike Antibody levels in people living with HIV who attended Visit 2 (2 weeks [+1 week window) post-second BNT162b2 COVID-19 vaccination series) and Visit 3 (6 months [± 2 weeks] post-primary BNT162b2 COVID-19 vaccination series) (n= 12). Two patients had significantly higher antibody levels at Visit 3, compared to Visit 2. b Quantitative assessment of SARS-CoV-2 Spike Antibody levels in people living with HIV (n= 26) at Visit 3 (6 months [± 2 weeks] post-primary BNT162b2 COVID-19 vaccination series)

Fig. 2
figure 2

Immunologic T cell subset testing. a SARS-CoV-2-specific T cell response after intracellular cytokine staining assay (ICS, 6 h). Cytokine production was defined as IFγ+TNFα–, IFγ+TNFα+ and IFγ-TNFα+ combined. Cytokine production was measured within live CD3+CD4+CD8- cells for CD4 response and live CD3+CD4-CD8+ cells for CD8 response. b SARS-CoV-2-specific T cells after activation induced marker assay (AIM, 20 h). SARS-CoV-2-specific CD4 T cells and CD8 T cells were defined as live CD3+CD4+CD8-OX40+CD137+ cells and CD3+CD4+CD8-CD69+CD137+ cells, respectively

Fig. 3
figure 3

Reactogenicity symptoms 1-week post-3rd BNT162b2 COVID-19 vaccine booster in People living with HIV, aged ≥55 years

Availability of data and materials

The data that support the findings of this study are available but protected under Institutional Review Board at Yale given the sensitive nature of patient health information and, thus, restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Yale.


  1. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to COVID-19. N Engl J Med. 2021;385(26):2413–20.

    CAS  Article  PubMed  Google Scholar 

  2. Jabłońska K, Aballéa S, Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health. 2021;198:230–7.

    Article  PubMed  Google Scholar 

  3. Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184(6):1589–603.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: implications for COVID-19 vaccines. J Med Virol. 2022;94(4):1330–5.

    CAS  Article  PubMed  Google Scholar 

  5. Tuan JJ, Zapata H, Critch-Gilfillan T, et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV [published online ahead of print, 2021 Oct 10]. HIV Med. 2021.

  6. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244–6.

    Article  PubMed  Google Scholar 

  7. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. August 16, 2021.

  8. Gdoura M, Ghaloum FB, Hamida MB, Chamsa W, Triki H, Bahloul C. Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans. Sci Rep. 2022;12(1):11298.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022;8(1):10.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize omicron. Nature. 2022;603(7901):488–92.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine. N Engl J Med. 2022;386(20):1910–21.

    CAS  Article  PubMed  Google Scholar 

  12. Tau L, Turner D, Adler A, et al. SARS-CoV-2 humoral and cellular immune responses of patients with hiv after vaccination with BNT162b2 mRNA COVID-19 vaccine in the Tel-Aviv Medical Center. Open Forum Infect Dis. 2022;9(4):ofac089.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references


We would like to acknowledge these individuals for their contributions: Study procedures and data collection: All authors. Immunologic testing: Syim Salahuddin, Omkar Chaudhary, Brinda Emu. Research coordination: Laurie Andrews (Yale AIDS Program, Yale University School of Medicine), Linda Ryall (Yale Center for Clinical Investigation, Yale University School of Medicine), and Anousheh Behnegar (Yale AIDS Program, Yale University School of Medicine).

Research statement

All methods were carried out in accordance with relevant guidelines and regulations.


No funding.

Author information

Authors and Affiliations



All authors had full access to the study data and are responsible for data integrity and accurate data analysis. Concept and design: OO, JT, and LB. Acquisition of data: All authors. Analysis, or interpretation of data: All authors. Drafting of the manuscript: JT, OO. Revision of the manuscript: All authors. Statistical analysis: JK. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jessica J. Tuan.

Ethics declarations

Ethics approval and consent to participate

This study received Yale Human Investigations Committee and Institutional Review Board approval (HIC # 200030266) and written informed consent from subjects was obtained.

Consent for publication

Not applicable.

Competing interests

No relevant financial disclosures, competing interests, or conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tuan, J.J., Zapata, H., Barakat, L. et al. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infect Dis 22, 744 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • HIV
  • COVID-19
  • SARS-CoV-2
  • Immunogenicity
  • BNT162b2